^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MAPK inhibitor

    Related drugs:
    Apply
    Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia (NCT05881265)
    Phase 2
    Shanghai Jiao Tong University School of Medicine
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    05/15/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    RARA • PML
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma (NCT05958719)
    Phase 2
    Institute of Hematology & Blood Diseases Hospit...
    Recruiting
    Last update posted :
    12/30/2024
    Initiation :
    03/02/2023
    Primary completion :
    12/30/2026
    Completion :
    03/02/2027
    IFNG • IL6 • TNFA • IL10 • IFNA1
    |
    azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
    Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia (NCT06532552)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    11/20/2024
    Initiation :
    07/29/2024
    Primary completion :
    08/01/2027
    Completion :
    08/01/2028
    BCL2
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide) • cladribine
    Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma (DEL Biomarker) (NCT06652152)
    Phase N/A
    Ruijin Hospital
    Not yet recruiting
    Last update posted :
    10/22/2024
    Initiation :
    10/30/2024
    Primary completion :
    05/30/2025
    Completion :
    12/30/2025
    BCL2
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epidaza (chidamide)
    Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (NCT06563778)
    Phase 2
    Chinese PLA General Hospital
    Not yet recruiting
    Last update posted :
    08/21/2024
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2026
    Completion :
    09/01/2028
    PD-1
    |
    decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine
    Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma (NCT04674683)
    Phase 3
    HUYABIO International, LLC.
    Active, not recruiting
    Last update posted :
    06/24/2024
    Initiation :
    08/12/2021
    Primary completion :
    12/01/2024
    Completion :
    10/01/2025
    BRAF
    |
    PD-L1 expression • BRAF mutation • PD-L1 negative
    |
    Opdivo (nivolumab) • Epidaza (chidamide)
    Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma. (NCT06393361)
    Phase 2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    PD-1
    |
    carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (NCT05083208)
    Phase 1/2
    Henan Cancer Hospital
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    02/20/2022
    Primary completion :
    06/30/2024
    Completion :
    01/01/2027
    ALK
    |
    ALK positive • ALK negative
    |
    Epidaza (chidamide) • parsaclisib (INCB50465)
    Chidamide Bridging for CAR-T Therapy (NCT05370547)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    05/25/2022
    Primary completion :
    06/30/2024
    Completion :
    06/30/2025
    BCL2 • BCL6 • PMAIP1
    |
    CD19 positive
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Epidaza (chidamide) • fludarabine IV • Carteyva (relmacabtagene autoleucel)
    Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) (KEPIDA-2) (NCT05833724)
    Phase 2
    Great Novel Therapeutics Biotech & Medicals Cor...
    Recruiting
    Last update posted :
    02/26/2024
    Initiation :
    04/01/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    ALK
    |
    ALK positive • ALK negative
    |
    Epidaza (chidamide)
    A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL (ABC) (NCT06220487)
    Phase 2
    Nanfang Hospital, Southern Medical University
    Recruiting
    Last update posted :
    01/24/2024
    Initiation :
    02/01/2024
    Primary completion :
    12/31/2025
    Completion :
    01/01/2028
    ABL1
    |
    Blincyto (blinatumomab) • prednisone • Epidaza (chidamide) • Nailike (olverembatinib)
    Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib (CINDERELLA) (NCT05464173)
    Phase 1/2
    Biyun Wang, MD
    Recruiting
    Last update posted :
    01/22/2024
    Initiation :
    07/01/2022
    Primary completion :
    02/01/2025
    Completion :
    05/01/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • fulvestrant • Epidaza (chidamide)
    Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) (NCT05281276)
    Phase 1
    Taipei Medical University Shuang Ho Hospital
    Recruiting
    Last update posted :
    12/14/2023
    Initiation :
    09/20/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    KRAS
    |
    KRAS mutation • RAS mutation • RAS wild-type
    |
    Epidaza (chidamide) • celecoxib oral
    Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia (NCT05566054)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    03/01/2022
    Primary completion :
    09/30/2024
    Completion :
    09/30/2025
    BCL2
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer (NCT02718066)
    Phase 1b/2
    HUYABIO International, LLC.
    Completed
    Last update posted :
    11/09/2023
    Initiation :
    08/01/2016
    Primary completion :
    09/01/2023
    Completion :
    09/01/2023
    EGFR • PD-L1 • ALK
    |
    Opdivo (nivolumab) • Epidaza (chidamide)
    A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients (NCT06087419)
    Phase 1/2
    Institute of Hematology & Blood Diseases Hospit...
    Not yet recruiting
    Last update posted :
    11/02/2023
    Initiation :
    10/30/2023
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    CD22
    |
    CD22 expression
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Besponsa (inotuzumab ozogamicin) • Epidaza (chidamide)
    Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer (NeoTEE) (NCT04465097)
    Phase 2
    First Affiliated Hospital, Sun Yat-Sen University
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    07/08/2020
    Primary completion :
    10/01/2023
    Completion :
    10/01/2023
    ER
    |
    ER positive • HER-2 negative
    |
    Epidaza (chidamide) • exemestane • goserelin acetate
    Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL (NCT04022005)
    Phase 2
    Sun Yat-sen University
    Completed
    Last update posted :
    09/11/2023
    Initiation :
    06/19/2019
    Primary completion :
    11/16/2022
    Completion :
    03/11/2023
    CD20
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Epidaza (chidamide)
    Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (NCT04231448)
    Phase 3
    Chipscreen Biosciences, Ltd.
    Active, not recruiting
    Last update posted :
    09/06/2023
    Initiation :
    05/21/2020
    Primary completion :
    07/05/2023
    Completion :
    03/01/2025
    MYC • BCL2 • CD20 • BCL6
    |
    CD20 positive • MYC rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide) • cyclophosphamide intravenous
    Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (NCT05983107)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    08/09/2023
    Initiation :
    07/20/2023
    Primary completion :
    07/15/2026
    Completion :
    07/15/2027
    HER-2 • ER • PIK3CA • PGR
    |
    HR positive • HER-2 negative • PIK3CA mutation • PGR positive • PIK3CA wild-type
    |
    everolimus • tamoxifen • fulvestrant • Epidaza (chidamide) • goserelin acetate
    A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL (NCT05931263)
    Phase 3
    The First Affiliated Hospital with Nanjing Medi...
    Recruiting
    Last update posted :
    07/04/2023
    Initiation :
    06/01/2023
    Primary completion :
    02/01/2026
    Completion :
    02/01/2028
    CD34
    |
    cytarabine • etoposide IV • Epidaza (chidamide) • carmustine • melphalan
    Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer (NCT04735068)
    Phase 2
    Abramson Cancer Center at Penn Medicine
    Active, not recruiting
    Last update posted :
    06/29/2023
    Initiation :
    04/09/2021
    Primary completion :
    08/21/2022
    Completion :
    12/01/2023
    KRAS
    |
    KRAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine
    Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI) (NCT04619316)
    Phase 2
    University Hospital, Essen
    Recruiting
    Last update posted :
    06/22/2023
    Initiation :
    02/05/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    TG
    |
    BRAF mutation • BRAF wild-type
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy (NCT05890287)
    Phase N/A
    Tianjin Medical University Cancer Institute and...
    Recruiting
    Last update posted :
    06/06/2023
    Initiation :
    05/16/2023
    Primary completion :
    05/01/2026
    Completion :
    10/01/2026
    HER-2
    |
    HER-2 negative
    |
    tamoxifen • fulvestrant • letrozole • Epidaza (chidamide) • anastrozole • exemestane
    A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy (NCT05527912)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    04/25/2023
    Initiation :
    02/24/2023
    Primary completion :
    09/01/2024
    Completion :
    12/01/2024
    MYC • BCL2
    |
    BCL2 expression • MYC expression
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)
    Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer (NCT05808582)
    Phase 2
    The First Affiliated Hospital with Nanjing Medi...
    Not yet recruiting
    Last update posted :
    04/14/2023
    Initiation :
    05/01/2023
    Primary completion :
    09/01/2023
    Completion :
    09/01/2024
    HER-2 • ER • PGR
    |
    ER positive • HR positive • HER-2 negative
    |
    fulvestrant • Epidaza (chidamide)
    Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy (NCT05806047)
    Phase 2
    Fudan University
    Not yet recruiting
    Last update posted :
    04/10/2023
    Initiation :
    05/01/2023
    Primary completion :
    05/01/2024
    Completion :
    11/01/2024
    ER
    |
    fulvestrant • Epidaza (chidamide)
    Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure (NCT05335473)
    Phase 1/2
    Henan Cancer Hospital
    Recruiting
    Last update posted :
    04/06/2023
    Initiation :
    05/13/2022
    Primary completion :
    05/01/2025
    Completion :
    11/01/2025
    HER-2
    |
    HER-2 negative
    |
    Halaven (eribulin mesylate) • Epidaza (chidamide)
    Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC (NCT05768503)
    Phase 3
    Sun Yat-sen University
    Recruiting
    Last update posted :
    03/14/2023
    Initiation :
    03/01/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    MSI • MLH1 • MSH6 • MSH2
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tyvyt (sintilimab) • oxaliplatin • irinotecan • Epidaza (chidamide) • leucovorin calcium
    Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer (NCT05163483)
    Phase 2
    Ruihua Xu
    Recruiting
    Last update posted :
    03/06/2023
    Initiation :
    07/01/2022
    Primary completion :
    12/01/2023
    Completion :
    12/01/2025
    PD-L1 • PD-L2
    |
    Avastin (bevacizumab) • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)
    Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer. (NCT05749575)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    03/01/2023
    Initiation :
    02/01/2023
    Primary completion :
    08/01/2023
    Completion :
    08/01/2024
    HER-2 • PD-L1
    |
    HER-2 negative
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)
    Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer (NCT05633914)
    Phase 2
    Hunan Cancer Hospital
    Recruiting
    Last update posted :
    02/20/2023
    Initiation :
    02/07/2023
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    albumin-bound paclitaxel • Epidaza (chidamide)
    A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC (NCT05519865)
    Phase 2
    Chipscreen Biosciences, Ltd.
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    10/26/2022
    Primary completion :
    10/01/2023
    Completion :
    10/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Epidaza (chidamide)
    Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial (SYSUCC-019) (NCT05390476)
    Phase 2
    wang shusen
    Recruiting
    Last update posted :
    11/04/2022
    Initiation :
    08/01/2022
    Primary completion :
    02/01/2024
    Completion :
    12/01/2024
    HER-2
    |
    HER-2 negative
    |
    capecitabine • Epidaza (chidamide)
    Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. (NCT05411380)
    Phase 2
    wang shusen
    Recruiting
    Last update posted :
    11/04/2022
    Initiation :
    10/03/2022
    Primary completion :
    04/01/2024
    Completion :
    04/01/2025
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    capecitabine • fulvestrant • letrozole • Epidaza (chidamide) • anastrozole • exemestane
    Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study (NCT05586841)
    Phase 1
    Beijing 302 Hospital
    Not yet recruiting
    Last update posted :
    10/19/2022
    Initiation :
    11/01/2022
    Primary completion :
    11/30/2024
    Completion :
    11/30/2025
    HER-2
    |
    HER-2 negative
    |
    Epidaza (chidamide) • AiRuiKang (dalpiciclib)
    Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer (NCT05085626)
    Phase 2
    Tianjin Medical University Cancer Institute and...
    Recruiting
    Last update posted :
    09/29/2022
    Initiation :
    02/08/2021
    Primary completion :
    10/31/2023
    Completion :
    12/31/2024
    HER-2 • BRCA
    |
    HR positive • HER-2 negative • BRCA mutation
    |
    AiRuiKa (camrelizumab) • Epidaza (chidamide) • AiRuiYi (fluzoparib)
    An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer (NCT05186545)
    Phase 2
    The First Affiliated Hospital of Zhengzhou Univ...
    Recruiting
    Last update posted :
    09/02/2022
    Initiation :
    07/01/2022
    Primary completion :
    01/01/2024
    Completion :
    07/01/2025
    HER-2
    |
    HR positive • HER-2 negative
    |
    fulvestrant • Epidaza (chidamide) • Sulanda (surufatinib)
    Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer (NCT02569489)
    Phase 1
    HUYABIO International, LLC.
    Withdrawn
    Last update posted :
    07/18/2022
    Initiation :
    12/01/2015
    Primary completion :
    12/01/2015
    Completion :
    12/01/2015
    HER-2
    |
    Herceptin (trastuzumab) • paclitaxel • Epidaza (chidamide)
    Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL (PDT-Ph-Like) (NCT03564470)
    Phase 2/3
    Nanfang Hospital of Southern Medical University
    Recruiting
    Last update posted :
    07/01/2022
    Initiation :
    02/14/2016
    Primary completion :
    08/30/2023
    Completion :
    08/30/2023
    ABL2
    |
    dasatinib • cytarabine • cyclophosphamide • Epidaza (chidamide)
    A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer (NCT05438706)
    Phase 2
    Fudan University
    Not yet recruiting
    Last update posted :
    06/30/2022
    Initiation :
    07/10/2022
    Primary completion :
    11/10/2023
    Completion :
    07/10/2024
    HER-2 • ER • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 expression • PGR expression
    |
    cisplatin • carboplatin • AiRuiKa (camrelizumab) • capecitabine • Epidaza (chidamide)